Introduction
Childhood acute lymphoblastic leukemia (ALL) accounts for 20-30% of all pediatric malignancies depending on age [1, 2] . Based on risk-adapted antileukemic therapy and improved supportive care, long-term survival rates of 85-90% could be achieved by the best contemporary treatment protocols of childhood ALL which was universally fatal disease in the early 1960s. The Children Oncology Group has recently reported the 88-95% 5-year event-free survival for low risk ALL patients diagnosed in the period 2006-2009 [3] . This development reflects international collaboration of large pediatric oncology groups, inclusion of patients in clinical trials, and systematic reporting of trials results [4] [5] [6] [7] [8] . It has been already shown that clinical trials in children with cancer result in significant improvement in their cure rates [9, 10] . However, few data on population-based long-term treatment results of childhood ALL with or without international collaboration have been published by pediatric oncology groups from Central or Eastern European countries [11] [12] [13] . Treatment results of 208 children with ALL treated in Lithuania from 1986 to 1994 were described in 1995 [14, 15] .
Due to historical reasons pediatric oncologists in Lithuania did not join international treatment protocols until recently, and because of a population of three million inhabitants conduction of national clinical trials was not possible. Children with cancer in Lithuania were treated according to protocols developed by international study groups that were published or obtained by direct personal contacts to study chairs. Children with ALL from late 1970s to 2008 were treated according to Berlin-Münster-Frankfurt (BFM)-based protocols. However, patients were neither prospectively registered nor enrolled into clinical trials.
In recent decade collaboration developed between Lithuanian pediatric oncologists and Nordic Society of Pediatric Hematology and Oncology (NOPHO). In April 2009, Lithuania joined the international NOPHO ALL-2008 treatment protocol. Here we present the population-based long-term treatment results of childhood ALL in Lithuania in 1992-2012 and discuss the benefits of international collaboration and joining the international treatment protocol.
2.
Patients and methods
Patients
From January 1992 to December 2012, 459 patients were diagnosed with ALL at the Center for Oncology and Hematology,
Children's Hospital, Affiliate of Vilnius University Hospital Santariškių Klinikos in which all children with ALL in Lithuania were treated. All children with T-lineage ALL (T-ALL) or B-cell precursor ALL (BCP) aged up to 16 years until January 2003 and subsequently aged up to 18 years (reflecting the age limit for patients in pediatric departments in Lithuania), including six patients with Down syndrome, were included into this population-based study. To evaluate trends in treatment results, the study period was divided into four periods according to the treatment and risk-stratification strategies used For the current study, data were retrieved retrospectively from paper files of the patients diagnosed prior to April 2009 or from the NOPHO ALL-2008 Register for subsequently diagnosed patients. Current status of each patient was checked before including into the study.
Median (75% range) follow-up of 314 patients remaining alive on April 1, 2013, was 10.9 (2.5-19.0) years. Of all 459 patients, 162 patients had a follow-up of ≥10.0 years. Four patients developed a second cancer after a median of 5.9 years from diagnosis of ALL.
2.2.
Diagnostic methods In addition, genotyping of thyopurinmethyltransferase by low activity alleles was introduced since joining the NOPHO ALL-2008 protocol as a mandatory test for individual 6-mercaptopurine (6-MP) dose adjustment during consolidation and maintenance therapy [17] .
Central nervous system (CNS) disease was defined by presence of leukemic blasts in diagnostic spinal tap and/or peripheral cranial nerve palsy, and/or intracranial leukemic infiltrates detected by imaging methods. Since 2009, CNS1 was defined as no blasts on cytospin, CNS2 as ≥1 and <5 cells per ml with blasts on cytospin, and CNS3 as ≥5 cells per ml with blasts on cytospin of diagnostic spinal tap.
2.3.
Response to therapy
In BFM-based era (1992-2008), prednisolone good response or prednisolone poor response was documented when <1000/mL or ≥1000/mL blasts, respectively, were found in peripheral blood after seven days of a prephase with prednisolone and intrathecal (i.th.) methotrexate (MTX). Bone marrow response was evaluated at the end of induction therapy on day 33. In the NOPHO ALL-2008, no prednisolone prephase was given, and bone marrow response was evaluated on day 29. 
Risk grouping
In 1992-1996, risk group assignment was based on the presence of hepatosplenomegaly, CNS involvement, response to prednisolone prephase and response to induction therapy (standard risk, SR: no hepatosplenomegaly, no CNS involvement, and no high risk criteria; intermediate risk, IR: hepatosplenomegaly and/or CNS involvement, and no high risk criteria; high risk, HR: prednisolone poor response and/or ≥5% blasts in bone marrow at the end of induction (day 33)).
In 1997-2002, same criteria were used, except SR patients had to be 2.0-11.9 years of age and to have WBC≤20 Â Other risk criteria remained the same as in previous periods.
In [2009] [2010] [2011] [2012] , NOPHO ALL-2008 protocol stratifying criteria were implemented. They had been in detailed described previously [4, 18] . Therapeutic risk group assignment was based on WBC< or ≥100 Â 10 
2009-2012 Period
Since April 2009, all BCP and T-ALL patients were enrolled to prospective NOPHO ALL-2008 protocol which had been described in detailed previously [4, 18] . Main differences in therapy compared with previous periods were: (i) cranial radiotherapy was omitted for all patients; (ii) L-asparaginase, i. /L did not reach remission on day 29 (≥5% blasts in BM) or MRD d79 ≥ 10 À3 ; (ii) T-ALL and BCP patients with WBC ≥ 100 had ≥25% blasts on day 15 and ≥5% after block A1, or ≥5% on day 29, or after block B1 MRD ≥ 10 À3 .
Overall, 20 patients received allogeneic HSCT during the study period in Lithuania in CR1 (N = 8) or ≥CR2 (N = 12). One patient is alive from the latter group while six patients out of eight who were transplanted in CR1, are alive without disease with a median (range) follow-up of 2.0 (0.2-9.0) years.
Statistical analysis
The Kruskal-Wallis test was used for comparison of continuous variables, and the chi-square test was used for comparison of categorized variables. Kaplan-Meyer method was used for determination of projected event-free survival (pEFS) and overall survival (pOS). pEFS was calculated from diagnosis to the date of assessment of induction failure, death in first complete remission (DCR1), relapse or the development of a second malignancy (whichever occurred first), or the last known follow-up date for event-free survivors. pOS was calculated from diagnosis to death from any cause. To estimate the cumulative incidences of relapse, induction failure or DCR1, all these events were considered as competing events [19] . Backward stepwise Cox regression analysis was performed to identify independent prognostic factors for differences in outcome. Two-sided P values of <0.05 were regarded as significant. Data were analyzed using statistical package for social sciences (SPSS) software for Windows, version 18.0 (SPSS, Chicago, IL, USA).
Results
Characteristics of all 459 study patients are presented in Table 1 . Incidence of childhood ALL in Lithuania was 3.2-3.6 cases per 100 000 of children per year during the study period with the dominance of boys (56%) vs. girls (44% /L for 55 T-ALL patients, respectively), and distribution of immunophenotype and cytogenetic aberrations, when the latter two characteristics were available, were in consistence with the findings of other childhood ALL study groups [20] [21] [22] .
Progressive improvement in pEFS and pOS was observed over time (Table 1 , Fig. 1A and B) . The 5-year pEFS improved from 50% AE 4% in 1992-1996 to 71% AE 4% in 2003-2008 (pooled P < 0.001), and the 5-year pOS improved from 57% AE 4% to 78% AE 4%, respectively (pooled P < 0.001). There was a trend for further survival improvement in 2009-2012, however, followup time for these patients was relatively short (Table 1 , Fig. 1A and B).
Advance was more prominent with a borderline significance for BCP patients with 5-year pEFS increasing from 68% AE 6% in 1997-2002 to 77% AE 4.5% in 2003-2008 (P = 0.065), with a trend for further improvement in 2009-2012 (pooled P = 0.043) ( Fig. 2A) . In contrast, survival rates were less prominent for T-ALL (Fig. 2B) . However, number of T-ALL patients was small . Out of four events for T-ALL patients in the recent period, two deaths appeared for HR patients due to septic complications during block therapy induced myelosuppression (N = 1) or cytomegalovirus pneumonia during maintenance (N = 1). The rest two events were relapses which are described below.
Five-year cumulative incidence of relapses reduced from 27% AE 4.5% in 1992-1996 to 14% AE 3.6% in 2003-2008 (P = 0.042) (Fig. 1A) . In 2009-2012, of the 82 patients, four developed early relapses so far (5%) after 0.6-1.4 years from diagnosis. One of them (IR, BCP) developed an isolated bone marrow relapse after parents abandoned the treatment. Another patient (IR, T-ALL) developed an isolated CNS relapse. The remaining two isolated bone marrow relapses occurred for HR ALL patients (T-ALL with hyperleukocytosis and BCP with MLL À rearrangement).
Incidence of CNS disease at diagnosis remained stable during the study period (Table 1) , while the 5-year cumulative incidence of CNS involving relapses decreased from 17% AE 3.9% in 1992-1996 to 9% AE 2.9% in 1997-2002 (P = 0.077), and after high dose MTX of 5 g/m 2 was introduced in 2003-2008, it decreased further down to 1% AE 1.0% (P < 0.001) (Fig. 1B) . Importantly, cumulative incidence of CNS involving relapses did not increase in 2009-2012 period (3-year cumulative incidence 2%) after cranial irradiation was omitted for all patients. However, follow-up is short for the recent period.
In contrast, cumulative incidence of induction failure and DCR1 remained high, albeit decreasing, all over the study FU, follow-up period; WBC, white blood cell count in peripheral blood at diagnosis; CNS, central nervous system; BM, bone marrow; BCP, B-cell precursor ALL; T-ALL, T-lineage ALL; NA, not available; HeH, high hyperdiploid karyotype (modal chromosome number >50); hypodiploid karyotype, modal chromosome number <45; 11q23/MLL, 11q23/MLL rearrangement; other, non-stratifying cytogenetic aberrations; IF, induction failure; DCR1, death in first complete remission; Rel, relapse; SMN, second malignancy; EFS, event-free survival. P value, determined after comparison of the values among different time-periods; ND, not determined: values were not compared and P value was not determined for immunophenotype or cytogenetic aberrations due to a large number of not available results in early time-periods, as well as for relapses due to the different follow-up time for patients in different time-periods.
period (Table 1) Cumulative incidence of DCR1 has not changed significantly over time (P = 0.237). The most common cause of DCR1 (61%) was treatment-related septic complications during myelosuppression (N = 30), followed by profuse bleeding (N = 4), high dose MTX induced gastroenteritis (N = 2), hemorrhagic pancreatitis (N = 1), or cerebral venous sinus thrombosis (N = 1). The exact reason was difficult to identify with certainty for 11 patients.
Univariate Cox regression analysis revealed WBC at diagnosis, CNS involvement at presentation and two earliest time-periods to have a significant prognostic impact for event (Table 2 ). However, after including these factors into Fig. 1 -Probability of event-free survival and cumulative incidence of any relapse (A) and probability of overall survival and cumulative incidence of any central nervous system relapse (B) in four consecutive time periods. Fig. 2 -Probability of event-free survival for B-cell precursor ALL patients (A) and probability of event-free survival for Tlineage ALL patients (B) in three consecutive time periods.
multivariate Cox regression analysis, CNS involvement lost its prognostic significance (Table 2 ).
Discussion
Survival rates of childhood ALL in Lithuania during all timeperiods were inferior to those reported by pediatric oncology groups from Western countries [4] [5] [6] 8, 23, 24] . However, the gap was decreasing over time from approximately 20% in the earliest period to almost approaching the rates reported by large international groups in the recent period. EFS rate has improved due to a decrease in rates of relapses and induction failure. However, cumulative incidence of induction failure or DCR1 still remained high. These findings have several implications. First, the Lithuanian health care system used to be characterized by inefficiency, poor health care and a lack of universal access [25] . The restricted access to internationally available research information and international collaboration led Lithuanian physicians to stay behind in the rapidly developing pediatric oncology. Supportive care and nursing practice was also inferior, with duties limited to technical procedures such as delivering prescribed drugs or procedures to the patients. However, with progress in nursing studies, the curriculum is now close to the Western European standards [26] .
Second, after gaining independency in 1990 the total health care expenditure per capita in US dollars in Lithuania was only 10% of that in the European Union countries [25] . In 1992-2002 there was a lack of both the supportive care measures such as broad spectrum antibacterial or antifungal drugs, and of antileukemic therapy. Due to health care reforms, health care expenditure per capita increased in 2011 to 1292 $ US, i.e., 35% of that in Western European countries [27] . Furthermore, since the year 2000, approximately 2 million litas (580 thousand euros) was additionally assigned on annual basis by the State for the treatment of children with cancer in Lithuania. This allowed the necessary antileukemic and supportive care drugs to be available for all childhood ALL patients and to perform all required diagnostic procedures in spite of increasing costs [28] . High toxic death rate remains the main challenge in treating children with ALL in Lithuania. It has been for many years close to the limit of unacceptable non-relapse mortality rate proposed for developing countries [29] . Careful monitoring, registration and analysis of toxic events in the NOPHO leukemia register [30] may have already improved the results, however due to short follow-up period this remains to be determined.
Conclusions
Cure rates of childhood ALL in Lithuania are steadily improving and are now approaching those reported by the largest international study groups. The reasons for positive effect are both a better financial support for treatment of children with cancer in Lithuania and international collaboration with joining international treatment protocol.
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